Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183:1113–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Reviews Clin Oncol. 2016;13:228–41.

Article  CAS  Google Scholar 

Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.

Article  PubMed  PubMed Central  Google Scholar 

Bryceson YT, March ME, Ljunggren H-G, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107:159–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503–10.

Article  CAS  PubMed  Google Scholar 

Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments. Nat Med. 2018;24:1178–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melaiu O, Lucarini V, Cifaldi L, Fruci D. Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol. 2020;10:3038.

Article  PubMed  PubMed Central  Google Scholar 

Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nat Immunol. 2020;21:835–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443–6.

Article  CAS  PubMed  Google Scholar 

Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94:259–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L, Matera L. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008;6:1–10.

Article  Google Scholar 

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-García M, Martínez-Garcia M, Menéndez S, Vazquez. I. NK cell infiltrates and HLA class I expression in primary HER2 + breast cancer predict and uncouple pathological response and disease-free survival. Clin Cancer Res. 2019;25:1535–45.

Article  CAS  PubMed  Google Scholar 

Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Reviews Clin Oncol. 2021;18:85–100.

Article  Google Scholar 

Fuentes-Antras J, Guevara-Hoyer K, Baliu-Piqué M, García-Sáenz JAn.;, Pérez-Segura P, Pandiella A, Ocaña A Adoptive cell therapy in breast cancer, editors. a current perspective of next-generation medicine. Front. Oncol. 2020, 2376.

Long EO, Sik Kim H, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227–58.

Article  CAS  PubMed  Google Scholar 

Cózar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11:34–44.

Article  PubMed  Google Scholar 

Tan E, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter K, Millar E. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer. 2009;100:405–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, Charaffe-Jaufret E, Birnbaum D, Moretta A, Olive D. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011;71:6621–32.

Article  CAS  PubMed  Google Scholar 

Mamessier E, Sylvain A, Thibult M-L, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Investig. 2011;121:3609–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ehlers FA, Beelen NA, van Gelder M, Evers TM, Smidt ML, Kooreman LF, Bos GM, Wieten L. ADCC-Inducing antibody trastuzumab and selection of KIR-HLA ligand mismatched donors enhance the NK Cell Anti-breast Cancer Response. Cancers (Basel). 2021;13:3232.

Article  CAS  PubMed  Google Scholar 

Wilson BE, Gorrini C, Cescon DW. Breast cancer immune microenvironment: from pre-clinical models to clinical therapies. Breast Cancer Res Treat 2021, 1–11.

Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, Yang S-R, Kurian A, Van Valen D, West R. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell 2018, 174, 1373–1387. e1319.

Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep. 2017;19:203–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banik G, Betts CB, Liudahl SM, Sivagnanam S, Kawashima R, Cotechini T, Larson W, Goecks J, Pai SI, Clayburgh DR. High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. In Methods Enzymol.; Elsevier: 2020; Volume 635, pp. 1–20.

Johnson BE, Creason AL, Stommel JM, Keck JM, Parmar S, Betts CB, Blucher A, Boniface C, Bucher E, Burlingame E. An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. Cell Rep Med 2022, 3.

Tsujikawa T, Mitsuda J, Ogi H, Miyagawa-Hayashino A, Konishi E, Itoh K, Hirano S. Prognostic significance of spatial immune profiles in human solid cancers. Cancer Sci. 2020;111:3426–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sorrelle N, Ganguly D, Dominguez AT, Zhang Y, Huang H, Dahal LN, Burton N, Ziemys A, Brekken RA. Improved multiplex immunohistochemistry for immune microenvironment evaluation of mouse formalin-fixed, paraffin-embedded tissues. J Immunol. 2019;202:292–9.

Article  CAS  PubMed  Google Scholar 

Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, Da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W. Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome. Cancer Discov. 2021;11:2014–31.

Article  PubMed  PubMed Central  Google Scholar 

Blise KE, Sivagnanam S, Banik GL, Coussens LM, Goecks J. Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma. NPJ Precision Oncol. 2022;6:10.

Article  CAS  Google Scholar 

Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci. 2012;109:2796–801.

Article  CAS  PubMed  Google Scholar 

Del Alcazar CRG, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017;7:1098–115.

Article  Google Scholar 

Mamessier E, Pradel LC, Thibult M-L, Drevet C, Zouine A, Jacquemier J, Houvenaeghel G, Bertucci F, Birnbaum D, Olive D. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol. 2013;190:2424–36.